Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal CancerBusiness Wire • 01/07/26
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026Business Wire • 01/06/26
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day TranscriptSeeking Alpha • 12/11/25
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025Business Wire • 12/03/25
Why Exelixis (EXEL) International Revenue Trends Deserve Your AttentionZacks Investment Research • 11/17/25
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference TranscriptSeeking Alpha • 11/10/25
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in NovemberBusiness Wire • 11/06/25
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateBusiness Wire • 11/04/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXELPRNewsWire • 10/28/25
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025Business Wire • 10/21/25
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The LancetBusiness Wire • 10/20/25
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025Business Wire • 10/18/25
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 YearsThe Motley Fool • 09/30/25
Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/24/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXELGlobeNewsWire • 09/10/25